Portfolio company
Coave Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
10 investors
Sectors
About
The company develops targeted gene therapies for patients with neurodegenerative and ocular diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Ray Therapeutics
The company develops optogenetic gene therapies to restore vision for patients with blinding retinal diseases.
GenSight Biologics
This company develops gene therapies for patients suffering from neurodegenerative retinal diseases and central nervous system disorders.
Corlieve Therapeutics
The company develops gene therapies for patients with refractory temporal lobe epilepsy and other severe neurological disorders.
Nightstar
This company develops gene therapies for patients with rare inherited retinal diseases that cause progressive blindness.
Borea Therapeutics
The company develops bio-conjugated viral vectors for gene therapy to treat patients with genetic or chronic diseases.
Shape Therapeutics
The company develops programmable RNA medicines and delivery systems for patients with genetic disorders and other hard-to-treat diseases.
PulseSight Therapeutics
This company develops non-viral gene therapies for patients with severe eye diseases including age-related macular degeneration.
AAVantgarde
This biotechnology company develops gene therapies for patients with inherited retinal diseases, such as Stargardt disease and Usher syndrome type 1B.